[Skip to Content]
[Skip to Content Landing]
Views 229
Citations 0
April 4, 2012

Life Expectancy After Treatment for Systolic Hypertension

Author Affiliations

Author Affiliation: Yale University School of Medicine, New Haven, Connecticut (steven.coca@yale.edu).

JAMA. 2012;307(13):1368-1369. doi:10.1001/jama.2012.389

To the Editor: In the study by Dr Kostis and colleagues,1 the main outcome measures were cardiovascular death and all-cause mortality. After 22 years, approximately 60% of participants from the Systolic Hypertension in the Elderly Program (SHEP) trial died, and less than 50% of the deaths were from a cardiovascular cause. There were no statistically significant differences in all-cause mortality by the various techniques the investigators used in analyzing these data (area between active and placebo survival curves, log-rank test, time to 70th percentile survival). Instead, there were statistically significant differences between the intervention and control groups only for the outcome of cardiovascular death.